SCHEMBL3633809

SCHEMBL3633809

CC(C)(C)c1n[nH]cc1CNc1cccc(-c2ccccn2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.40
AXL P30530 1/20 0.39
CNR1 P21554 1/20 0.38
NTRK1 P04629 1/20 0.38
MAPT P10636 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
HIF1A Q16665 5/20 0.36
CLK1 P49759 1/20 0.36
DYRK1A Q13627 1/20 0.36
ALDH1A1 P00352 1/20 0.35
ALPG P10696 1/20 0.35
HPGD P15428 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
CYP1A2 P05177 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635014 0.87 TRPV1 (0.43) AXLNTRK1HIF1ACYP1A2CYP3A4
SCHEMBL3637348 0.80 HTT (0.47) MAPTLMNAHTTALDH1A1HPGD
SCHEMBL3640679 0.79 MAOB (0.40) MAPTNPSR1TDP1LMNAHTT
SCHEMBL3641235 0.78 MAOB (0.43) MAPTNPSR1TDP1LMNAHTT
SCHEMBL3635913 0.78 MAPT (0.49) MAPTNPSR1TDP1LMNAHTT
SCHEMBL3637444 0.78 PRMT6 (0.41) METAP2AXLCNR1MAPTNPSR1
SCHEMBL3635936 0.78 PRMT6 (0.41) METAP2AXLMAPTNPSR1TDP1
SCHEMBL3637940 0.77 MAPT (0.44) NTRK1MAPTNPSR1TDP1LMNA
SCHEMBL3638362 0.77 GRK2 (0.47) MAPTNPSR1TDP1LMNAHTT
SCHEMBL3633513 0.76 MAPT (0.52) MAPTNPSR1TDP1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 METAP2 1677/4885AXL 2498/4885CNR1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.